• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Trista Morrison

Articles by Trista Morrison

Defining Value: DNDN, AMGN Show Innovation Isn't End-All

Aug. 8, 2011
By Trista Morrison

The Scariest Thing about Dendreon’s Implosion

Aug. 4, 2011
By Trista Morrison
As a biotech junkie, I’ll admit I was shocked to the core by Dendreon Corp.’s second-quarter admission that prostate cancer vaccine Provenge (Sipuleucel-T) is thus far not succeeding commercially. (See BioWorld’s news bulletin for details.) The most shocking part? Analyst and investor assumptions that Provenge’s poor performance is due not to reimbursement hurdles, as Dendreon claimed, but to an underlying lack of demand. Doctors and patients don’t want to use the product. Come again? Are you serious? Provenge is the first and only therapeutic cancer vaccine ever to gain FDA approval. I don’t have to tell anyone in the biotech...
Read More

Somaxon Backs Silenor Sales Efforts with $45M Financing

Aug. 4, 2011
By Trista Morrison
Somaxon Pharmaceuticals Inc. continued to slog through the crowded insomnia market with Silenor (doxepin) during the second quarter, growing net sales to $6.2 million – a 170 percent increase over the $2.3 million sold last quarter, and ahead of the $4 million analysts had expected.
Read More

Insmed Dives 53% as Rat Data Prompt Arikace Clinical Hold

Aug. 3, 2011
By Trista Morrison
Shares of Insmed Inc. dropped 52.5 percent Tuesday after data from a two-year rat carcinogenicity study prompted the FDA to slap a clinical hold on a pair of nascent Phase III trials with lung infection drug Arikace (liposomal amikacin for inhalation).
Read More

Complications of Competition: Navigating Lawsuits and More

Aug. 1, 2011
By Trista Morrison
The biotech industry's pipeline is burgeoning. The number of clinical projects under way at companies tracked by Deloitte Recap LLC has jumped 165 percent in the past decade, from 348 projects in 2000 to 922 projects in 2011 – and that doesn't even include pharma firms.
Read More

Despite Setbacks, Idera Still Hoeing the Long TLR Road

Aug. 1, 2011
By Trista Morrison

Scientists Singin’ on YouTube; Who’s Representin’ for Biotech?

July 29, 2011
By Trista Morrison
When I was blogging for BNET, one of my favorite posts chronicled the hilarious battle of the bands being waged between laboratory supply companies on YouTube. And it got me thinking: why do lab supply firms get to have all the fun? You’ve got Roche AG’s diagnostic division using a Motley-Poison-Whitesnake style rock anthem and power ballad to promote its xCELLigence cellular analysis system. And there’s Bio-Rad Laboratories Inc., the forefathers of funniness, with their “We Are the World” tribute to PCR and my personal favorite, the Village People spoof “GTCA.” [youtube]http://www.youtube.com/watch?v=CQEaX3MiDow&feature=related[/youtube] But who’s representin’ for biotech? Please post in...
Read More

Celgene Delivers Again: Top And Bottom Line Strong in Q2

July 29, 2011
By Trista Morrison
Celgene Corp., the poster child of what a big biotech growth story should be, delivered yet another happy ending in the second quarter.
Read More

Reverse Merger Returns Vary Widely: Weighing the Risk

July 25, 2011
By Trista Morrison
Investors in Novacea Inc. prior to its reverse merger with Transcept Pharmaceuticals Inc. three years ago might be forgiven for saying, "I told you so."
Read More

Form 10 Offers Alternative to IPO, Reverse Merger Listing

July 25, 2011
By Trista Morrison
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 133 134 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe